UPDATE: Bank of America Reiterates on Edwards Lifesciences on Unique Investment Opportunity

In a report published Monday, Bank of America analyst Bob Hopkins reiterated a Neutral rating on

, and raised the price target from $67.00 to 75.00. In the report, Bank of America noted, “Over the next 5+ years, there is no other new product opportunity in medtech of a similar pot'l size as the TAVI market, and EW is the only stand-alone name. EW has this opportunity at a time when large-cap medtech is severely growth challenged and threatened by margin uncertainty given health care reform, but flush with cash. We believe TAVI will stand alongside coronary stents as a core technology in the catheterization lab of the future.” Edwards Lifesciences closed on Friday at $72.13.